榮暉控股(08213.HK):華胤生物科技22日在中國推出新祛斑美白護膚品
格隆匯 12 月 22日丨榮暉控股(08213.HK)公告,據華胤(深圳)生物科技有限公司("華胤生物科技")(由榮暉深圳管理公司)所告知,華胤生物科技於2020年12月22日在中國正式推出一系列新的祛斑美白護膚品,品牌名為"NA+NP BEAUTYMARKING TIME NONER APOSTO BEAUTY MARKING TIME"。
產品(其包括潔面乳、噴霧、精華液、眼部精華、面霜及面膜)由華胤生物科技使用"PH450"生物DNA代謝酶技術("PH450酶技術")開發。
公司獲告知,華胤生物科技於2020年獲得PH450酶技術的專有權,並於同年取得"PH450酶的大量製備方法"的專利權。
公司亦獲告知,"PH450的大量製備方法"的發明者為沃納·阿爾伯,其乃瑞士生物學家,獲得一九七八年諾貝爾醫學及生理學獎,並被稱為"全球細胞酶父"。PH450酶技術為全球領先的生命科學技術,可以直接溶解及代謝肌膚細胞色素、毒素和炎症問題,促進細胞循環及排出細胞沉澱毒素,並通過添加端粒酶激活技術提高細胞存活,實現"長壽蛋白"再生,使線粒體細胞器更新,激活細胞能量及更新肌膚。
通過使用PH450酶技術,產品有望排出肌膚暗黃色素,調節細胞代謝更新,改善暗黃膚色,使肌膚恢復健康活力、嫩白及更新。
根據"2020年中國袪斑護膚品市場行業前景、現狀分析報告"的統計數據,約98%的中國女性有不同程度的肌膚斑點,且85%以上的女性年齡介乎18至45歲。考慮到客户期望及現代女性在美容及肌膚保養方面的消費能力不斷提高,祛斑美白護膚品具有巨大的市場需求及增長潛力。
因此,通過將女性作為主要目標客户,董事會相信產品將深受市場歡迎及認可,日後將成為一款具市場競爭力的產品。
董事會認為,華胤生物科技推出的產品能夠幫助集團擴展保健業務,其有利於集團收入來源多元化及提升其競爭力,為集團的業務發展創造新的增長動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.